Home Other Building Blocks 1009298-09-2
1009298-09-2,MFCD16660191
Catalog No.:AA00035B

1009298-09-2 | AZD8055

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$12.00   $9.00
- +
10mg
98%
in stock  
$43.00   $30.00
- +
50mg
99%
in stock  
$187.00   $131.00
- +
100mg
99%
in stock  
$306.00   $215.00
- +
1g
98%
in stock  
$1,537.00   $1,076.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00035B
Chemical Name:
AZD8055
CAS Number:
1009298-09-2
Molecular Formula:
C25H31N5O4
Molecular Weight:
465.5447
MDL Number:
MFCD16660191
SMILES:
OCc1cc(ccc1OC)c1ccc2c(n1)nc(nc2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C
Properties
Computed Properties
 
Complexity:
659  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
2  
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
5  
XLogP3:
2.6  

Literature

Title: Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.

Journal: Molecular oncology 20140501

Title: mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection.

Journal: Virology 20140301

Title: PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20130801

Title: Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

Journal: Bioorganic & medicinal chemistry letters 20130301

Title: Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.

Journal: British journal of cancer 20120925

Title: The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

Journal: Leukemia 20120601

Title: Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis.

Journal: The Biochemical journal 20120515

Title: TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO.

Journal: Cell metabolism 20120502

Title: Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).

Journal: Cancer research 20120401

Title: Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines.

Journal: Experimental neurology 20120201

Title: Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

Journal: PloS one 20120101

Title: Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1.

Journal: The Journal of biological chemistry 20111118

Title: Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

Journal: Cancer research 20110801

Title: mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Journal: Cancer discovery 20110617

Title: mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.

Journal: Cancer research 20110615

Title: Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.

Journal: Biochemical Society transactions 20110401

Title: Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice.

Journal: British journal of cancer 20110329

Title: Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

Journal: Journal of medicinal chemistry 20110310

Title: Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

Journal: Bioorganic & medicinal chemistry letters 20100801

Title: Mammalian autophagy: core molecular machinery and signaling regulation.

Journal: Current opinion in cell biology 20100401

Title: AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Journal: Cancer research 20100101

Title: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

Journal: Nature 20090716

Title: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Journal: Current biology : CB 20040727

Title: Regulation of longevity and stress resistance by Sch9 in yeast.

Journal: Science (New York, N.Y.) 20010413

Title: Chresta CM, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res, 2010, 70(1), 288-298.

Title: You W, et al. Inhibition of mammalian target of rapamycin attenuates early brain injury through modulating microglial polarization after experimental subarachnoid hemorrhage in rats. J Neurol Sci. 2016 Aug 15;367:224-31.

Title: Kawata T, et al. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Cancer Sci. 2017 Oct 27.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:1009298-09-2 Molecular Formula|1009298-09-2 MDL|1009298-09-2 SMILES|1009298-09-2 AZD8055